Price History
The Nifty Pharma index has significantly outperformed the broader market, increasing by 11% over the past month while the Nifty 50 experienced a decline of 3.6%. Notable standouts in this sector include Gland Pharma with a impressive 27% gain, Laurus Labs at 23%, and Biocon showing a 21% rise.
Pharmaceutical companies IPCA Labs, Biocon, Laurus Labs, Gland Pharma, Aurobindo, Sun Pharma, Wockhardt, Lupin, Divi's, Zydus, Torrent, JB Chem, Glenmark, and Ajanta have surged to their highest levels in the past year. Other notable gains were seen among stocks like these.
Gland Pharma just completed a significant block trade on NSE, selling 68,258 shares for approximately Rs. 15.48 crore, with each share priced at around Rs. 2,267.30.
Gland Pharma experiences a 15% surge in share prices following an impressive 86% year-on-year increase in net profit for Q4. However, the Nifty Bank and Midcap indices experienced a dip, with the Nifty Bank dropping by 173 points to 53,537 and the Midcap index falling by 93 points to 60,474.
Investment advisor Motilal Oswal suggests purchasing shares of Gland Pharma at its current price of Rs. 2159.2, indicating a positive outlook for the company's future performance.
Gland Pharma reported a significant 96.6% increase in net profit, with Kotak Securities setting a new target price of ₹2,175. On the other hand, KIMS experienced a revenue growth of 35.3%, but its Profit After Tax (PAT) decreased. Aarti Drugs saw a 6.4% increase in Q4 revenue, but their margins took a hit.
Elara Capital maintains its optimistic view on Gland Pharma, recommending buyers with a projected price of INR 2,306.
Gland Pharma experienced a significant surge following its recent results, with analysts like Janhavi Ladda considering both the short-term catalysts and long-term sustainability of this uptrend.
Gland Pharma reported a substantial 96.6% year-on-year increase in Q4 profits, primarily due to successful US launches and growth in their CDMO segment. Revenue also increased by 22.3%, totaling ₹1,742.7 crore, leading to the announcement of a ₹20/share dividend. Despite this positive news, shares on BSE dropped by 1.8% to ₹1,861.
Gland Pharma's Q4 earnings jumped 97%, fueling a 14.5% annual revenue growth for the fiscal year. The company proposes to distribute a dividend of Rs 20 per share, reflecting strong financial performance.
Gland Pharma has released its Q4 earnings, with notable highlights showcased. Stay tuned for more details on their financial performance in the recent quarter.
Gland Pharma's Q4 net profit experienced a remarkable 95% year-on-year increase, reaching INR 3.7 billion. The company also reported a 22% growth in revenue during the same period, amounting to INR 17.4 billion.
Gland Pharma has declared a dividend of INR 20 per share for their fiscal year 2026, with the record date being August 11, 2026. Their audited financial results were approved, and auditor opinions remain unmodified.
Gland Pharma completed a significant block deal on the NSE, trading 152,565 shares worth approximately INR 27.6 crore at a price of INR 1,805.9 per share.
Gland Pharma has executed a significant block trade on the NSE, with 100,113 shares traded at approximately Rs. 1736.30, translating to a total value of around Rs. 17.38 crore.
ICICI Securities predicts a moderate 7.2% revenue growth for the pharmaceutical sector in Q4 FY26, with EBITDA and PAT forecasted to decrease. Top picks include Sun Pharma, Aurobindo, Alkem, Gland, and Torrent, which could benefit from a domestic focus. Lupin shows signs of resilience.
Starting from April 6, 2026, Gland Pharma has appointed Prasadha Rao Lysetti as their Senior Vice President and Head of Operations. With over 25 years of pharmaceutical operational experience under his belt, having worked with prominent companies like Dr. Reddy's and Glenmark, Lysetti brings valuable industry knowledge to the team.
Gland Pharma experiences a notable increase in trading activity, indicating heightened investor interest.